Page last updated: 2024-10-25

deferoxamine and Pancytopenia

deferoxamine has been researched along with Pancytopenia in 2 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.

Research Excerpts

ExcerptRelevanceReference
"Pancytopenia is difficult to manage in patients with this disorder."1.32Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin. ( Erduran, E; Hacisalihoglu, S; Ozoran, Y, 2003)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Erduran, E1
Hacisalihoglu, S1
Ozoran, Y1
Ammon, A1
Rumpf, KW1
Hommerich, CP1
Behrens-Baumann, W1
RĂ¼chel, R1

Other Studies

2 other studies available for deferoxamine and Pancytopenia

ArticleYear
Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin.
    Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:4

    Topics: Blood Cell Count; Bone Marrow; Child, Preschool; Deferoxamine; Disease Susceptibility; Dyskeratosis

2003
[Rhinocerebral mucormycosis during deferoxamine therapy].
    Deutsche medizinische Wochenschrift (1946), 1992, Sep-18, Volume: 117, Issue:38

    Topics: Adult; Blindness; Brain Diseases; Cellulitis; Combined Modality Therapy; Deferoxamine; Female; Human

1992